A Single-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Multiple-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-709478 in Healthy Subjects

Trial Profile

A Single-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Multiple-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-709478 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs ACT 709478 (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals
  • Most Recent Events

    • 26 Jul 2017 Status changed from not yet recruiting to recruiting.
    • 06 Jul 2017 Planned initiation date changed from 30 Jun 2017 to 24 Jul 2017.
    • 29 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top